Omalizumab chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response

MLA

Nettis E., et al. Omalizumab Chronic Spontaneous Urticaria: Efficacy, Safety, Predictors of Treatment Outcome, and Time to Response. Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..26b016db69b86ae64d4f09769eca731e&authtype=sso&custid=ns315887.

APA

Nettis E., Cegolon L., Di Leo E., Lodi Rizzini F., Detoraki A., & Canonica G. W. (2018). Omalizumab chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.

Chicago

Nettis E., Cegolon L., Di Leo E., Lodi Rizzini F., Detoraki A., and Canonica G. W. 2018. “Omalizumab Chronic Spontaneous Urticaria: Efficacy, Safety, Predictors of Treatment Outcome, and Time to Response,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..26b016db69b86ae64d4f09769eca731e&authtype=sso&custid=ns315887.